Semaglutide reduces the need for loop diuretics and has positive effects on symptoms,
physical limitations, and body weight in patients with heart failure with preserved
ejection fraction (HFpEF), regardless of diuretic use,
according to a study presented
at the European Society of Cardiology Heart Failure 2024, held from May 11 to 14
in Lisbon, Portugal.